SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsFaı̈ez Zannad, Milton Packer, Anne Pernille Ofstad et al.|The Lancet|2020Cited by 1.4k
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes StatusStefan D. Anker, Milton Packer, Waheed Jamal et al.|Circulation|2020Cited by 350
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without DiabetesGerasimos Filippatos, Stefan D. Anker, Martina Brueckmann et al.|Circulation|2022Cited by 126